Hagop M. Kantarjian
Hagop Kantarjian is one of the most prolific leukaemia investigators alive, and helped bring more than a dozen leukaemia drugs to approval.
Has chaired MD Anderson's leukemia department since 1999 and led pivotal trials in CML (imatinib, dasatinib, ponatinib), ALL (inotuzumab, blinatumomab combinations), and AML. A vocal advocate on cancer drug pricing.
| Title | Journal | Year |
|---|---|---|
| Inotuzumab Ozogamicin versus Standard Therapy for Acute Lymphoblastic Leukemia | New England Journal of Medicine | 2016 |
| Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia | New England Journal of Medicine | 2017 |
Pages like this
not linked directly; found by shared links- ProductInotuzumab ozogamicin
Shares INO-VATE ALL, INO-VATE: inotuzumab ozogamicin, a CD22 antibody-drug conjugate, versus chemotherapy for relapsed adult B-cell ALL, Acute lymphoblastic leukaemia.
- TargetCD22
Shares INO-VATE ALL, INO-VATE: inotuzumab ozogamicin, a CD22 antibody-drug conjugate, versus chemotherapy for relapsed adult B-cell ALL, Acute lymphoblastic leukaemia.
- InstitutionGIMEMA
Shares Blinatumomab, Imatinib, Chronic lymphocytic leukaemia, Acute lymphoblastic leukaemia.
- TermLeukaemia (tissue type)
Shares Blinatumomab, Imatinib, Chronic lymphocytic leukaemia, Acute lymphoblastic leukaemia.
- PairingCaution: inotuzumab before transplant (veno-occlusive disease)
Shares INO-VATE: inotuzumab ozogamicin, a CD22 antibody-drug conjugate, versus chemotherapy for relapsed adult B-cell ALL, Acute lymphoblastic leukaemia.
- InstitutionSeoul St. Mary's Hospital
Shares Imatinib, Acute lymphoblastic leukaemia, Acute myeloid leukaemia.
- TrialTOWER
- TermTumour lysis syndrome (TLS)
Shares Chronic lymphocytic leukaemia, Acute lymphoblastic leukaemia, Acute myeloid leukaemia.